上皮-间充质转化与非小细胞肺癌EGFR—TKIs获得性耐药关系的研究进展

Research progress in acquired resistance of EGFR-TKIs associated with epithelial to mesenchymal transition in non-small cell lung cancer Feng

目前，表皮生长因子受体－酪氨酸激酶抑制剂（epidermal growth factor receptor tyrosine kinase inhibitors，EGFR—TKIs）在非小细胞肺癌中的获得性耐药机制已经成为研究的热点，且针对相应机制治疗EGFR—TKIs获得性耐药非小细胞肺癌的药物也已被研发应用，然而部分获益的患者最终仍然出现了耐药的现象，更多未知的耐药机制仍有待研究探索。近期研究发现，上皮-间充质转化（epithelial to mesenchymal transition，EMT）也与非小细胞肺癌EGFRTKIs获得性耐药具有一定的相关性，它是一个可诱发肿瘤细胞获得迁移和侵袭能力、促进肿瘤进展的生物学过程。因此，本文主要就EMT的发生机制、EMT与EGFR—TKIs获得性耐药相关关系的研究进展进行详细综述。

Currently, the mechanisms of resistance to epidermal growth factor receptor-tyrosine kinase inhibitors （EGFR TKIs） in non-small cell lung cancer （NSCLC） have been a research hotspot. And the drugs which aim to reverse EGFR-TKIs resistance have been used in clinic. However, some patients who responded well to EGFR TKIs at first developed drug resistance finally, so more mechanisms of resistance to EGFR-TKIs need to be lucubrated. The epithelial to mesenchymal transition （EMT） is a biological process which can induce the migration and invasion in tumor cells and enhance the tumor progression, and is related with acquired resistance ot＂ EGFR-TKIs in NSCLC. Thus, this paper reviews the mechanism of EMT as well as the relationship of EMT and acquired resistance of EGFR TKIs in NSCLC.